We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+63.6%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$171M
AUM Growth
+$6.45M
Cap. Flow
-$10.6M
Cap. Flow %
-6.21%
Top 10 Hldgs %
71.58%
Holding
38
New
13
Increased
7
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
MLNT
Melinta Therapeutics, Inc. Common Stock
MLNT
+$9.64M
2
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$7.93M
3
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$3.23M
4
OPNT
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
+$3.22M
5
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$3.15M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$15.7M
2
BSTC
BioSpecifics Technologies Corp.
BSTC
+$8.98M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$5.62M
4
CORV
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
+$4.55M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$4.24M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NEOS
26
DELISTED
Neos Therapeutics, Inc
NEOS
$1.1M 0.65%
+227,919
New +$1.29M
FSTX
27
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$856K 0.5%
+17,763
New +$890K
VYNT
28
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
$639K 0.37%
4,096
-5,181
-56% -$767K
SCYX icon
29
SCYNEXIS
SCYX
$38.7M
$539K 0.32%
+5,610
New +$662K
SRTS icon
30
Sensus Healthcare
SRTS
$51M
$317K 0.19%
+37,858
New +$274K
DOVA
31
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$145K 0.08%
+6,900
New +$164K
ACAD icon
32
Acadia Pharmaceuticals
ACAD
$4.3B
– –
-194,900
Closed -$2.98M
ADMA icon
33
ADMA Biologics
ADMA
$2.03B
– –
-831,731
Closed -$3.75M
RIGL icon
34
Rigel Pharmaceuticals
RIGL
$734M
– –
-149,659
Closed -$4.24M
SNDX icon
35
Syndax Pharmaceuticals
SNDX
$1.98B
– –
-198,373
Closed -$1.39M
MTVA
36
MetaVia Inc
MTVA
$8.68M
– –
-2
Closed -$1.05M
CFMS
37
DELISTED
Conformis, Inc. Common Stock
CFMS
– –
-24,644
Closed -$770K
NVIV
38
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
– –
-104
Closed -$132K
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Stonepine Capital Management held 38 positions worth $171M, up 3.9% from $165M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Stonepine Capital Management withdrew a net $10.6M in Q3 2018, closing 7 positions and reducing 9 holdings. Its most notable exit was Rigel Pharmaceuticals, an estimated $4.24M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in Oxford Immunotec Global PLC Ordinary Shares worth $3.67M.

  • Stonepine Capital Management's largest Q3 2018 buy was Oxford Immunotec Global PLC Ordinary Shares: 225,877 shares worth $3.67M.
  • Stonepine Capital Management added most to Melinta Therapeutics, Inc. Common Stock in Q3 2018, an estimated $9.64M increase.
  • Stonepine Capital Management's biggest Q3 2018 reduction was Amarin Corp, cutting an estimated $15.7M.
  • Stonepine Capital Management fully exited Rigel Pharmaceuticals in Q3 2018, selling an estimated $4.24M.
  • Stonepine Capital Management's ten largest holdings make up 72% of its $171M portfolio in Q3 2018.
  • Stonepine Capital Management opened 13 new positions and closed 7 in Q3 2018.
  • Stonepine Capital Management's portfolio value rose 3.9% quarter-over-quarter to $171M.

Based on Stonepine Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.